Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model
The Journal of Clinical Pharmacology · 2024-09 · 64 (9) · 1083-1094
DOI: 10.1002/jcph.2452 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 02.05.2024. Verfasst von Marc Codaccioni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Certara Predictive Technologies Division, Certara UK Limited, Sheffield, UK. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Models, Biological, Liver, Midazolam. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
The rapid growth in the use of pediatric physiologically based pharmacokinetic (PBPK) models, particularly for regulatory applications, has focused emphasis on model verification and ensuring system parameters are robust, including how these change with age. Uncertainty remains regarding the ontogeny of some enzymes and transporters, in this study 2 published ontogeny profiles for hepatic CYP3A4 were compared. Clinical pharmacokinetic data on 4 intravenously administered CYP3A4 substrates (alfentanil, fentanyl, midazolam, and sildenafil) used across the pediatric age range was collected from the literature. The PBPK models were verified in the adult population and then used to compare the Salem and a modified Upreti ontogeny profiles for CYP3A4 in terms of parent drug clearance and area under the curve from birth onward. Overall, the modified Upreti ontogeny profile resulted in 15 out of 17 age‐related predictions within 2‐fold and 12 out of 17 predictions within 1.5‐fold ranges of observed values, for the Salem ontogeny these values were 12 out of 17 and 8 out of 17, respectively. The Upreti ontogeny profile performed better than Salem, average fold error and absolute average fold error were 1.14 and 1.35 compared to 1.56 and 1.90, respectively. Identifying the optimal CYP3A4 ontogeny is important for regulatory use of PBPK especially given the number of drugs cleared by this enzyme. This study broadens the evidence from previous studies that Upreti is more favorable than Salem, but further work is needed especially in the neonatal and early infant age range.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Certara Predictive Technologies Division, Certara UK Limited, Sheffield, UK.
ORCID-Profile: Trevor N Johnson
Zitieren
APA
Codaccioni, M., Southall, R. L., Dinh, J., & Johnson, T. N. (2024). Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model. The Journal of Clinical Pharmacology, 64(9), 1083-1094. https://doi.org/10.1002/jcph.2452
Vancouver
Codaccioni M, Southall RL, Dinh J, Johnson TN. Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model. The Journal of Clinical Pharmacology. 2024;64(9):1083-1094. doi:10.1002/jcph.2452
BibTeX
@article{Codaccioni2024,
author = {Codaccioni, Marc and Southall, Rosalind L and Dinh, Jean and Johnson, Trevor N},
title = {Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
volume = {64},
number = {9},
pages = {1083--1094},
doi = {10.1002/jcph.2452}
}
EUVIMED